JP2017509335A5 - - Google Patents

Download PDF

Info

Publication number
JP2017509335A5
JP2017509335A5 JP2016555472A JP2016555472A JP2017509335A5 JP 2017509335 A5 JP2017509335 A5 JP 2017509335A5 JP 2016555472 A JP2016555472 A JP 2016555472A JP 2016555472 A JP2016555472 A JP 2016555472A JP 2017509335 A5 JP2017509335 A5 JP 2017509335A5
Authority
JP
Japan
Prior art keywords
fusion protein
residue
multimeric fusion
region
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016555472A
Other languages
English (en)
Japanese (ja)
Other versions
JP6851199B2 (ja
JP2017509335A (ja
Filing date
Publication date
Priority claimed from GB201403914A external-priority patent/GB201403914D0/en
Priority claimed from GB201403915A external-priority patent/GB201403915D0/en
Priority claimed from GBGB1405955.4A external-priority patent/GB201405955D0/en
Priority claimed from GB201412648A external-priority patent/GB201412648D0/en
Application filed filed Critical
Priority claimed from PCT/EP2015/054688 external-priority patent/WO2015132365A1/en
Publication of JP2017509335A publication Critical patent/JP2017509335A/ja
Publication of JP2017509335A5 publication Critical patent/JP2017509335A5/ja
Application granted granted Critical
Publication of JP6851199B2 publication Critical patent/JP6851199B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016555472A 2014-03-05 2015-03-05 多量体Fcタンパク質 Expired - Fee Related JP6851199B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GB201403914A GB201403914D0 (en) 2014-03-05 2014-03-05 Proteins
GB201403915A GB201403915D0 (en) 2014-03-05 2014-03-05 Proteins
GB1403915.0 2014-03-05
GB1403914.3 2014-03-05
GBGB1405955.4A GB201405955D0 (en) 2014-04-02 2014-04-02 Proteins
GB1405955.4 2014-04-02
GB1412648.6 2014-07-16
GB201412648A GB201412648D0 (en) 2014-07-16 2014-07-16 Proteins
PCT/EP2015/054688 WO2015132365A1 (en) 2014-03-05 2015-03-05 Multimeric fc proteins

Publications (3)

Publication Number Publication Date
JP2017509335A JP2017509335A (ja) 2017-04-06
JP2017509335A5 true JP2017509335A5 (enExample) 2018-04-12
JP6851199B2 JP6851199B2 (ja) 2021-03-31

Family

ID=52697365

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016555472A Expired - Fee Related JP6851199B2 (ja) 2014-03-05 2015-03-05 多量体Fcタンパク質

Country Status (13)

Country Link
US (1) US20170081406A1 (enExample)
EP (1) EP3114137A1 (enExample)
JP (1) JP6851199B2 (enExample)
KR (1) KR20160127821A (enExample)
CN (1) CN106132994A (enExample)
AU (1) AU2015226101B2 (enExample)
BR (1) BR112016020377A2 (enExample)
CA (1) CA2939201A1 (enExample)
IL (1) IL247246A0 (enExample)
MX (1) MX2016010953A (enExample)
RU (1) RU2016139022A (enExample)
SG (1) SG11201606596PA (enExample)
WO (1) WO2015132365A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016010951A (es) 2014-03-05 2016-11-29 Ucb Biopharma Sprl Proteinas de fc multimericas.
EP4299595A3 (en) 2014-05-02 2024-03-13 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc constructs
GB201511787D0 (en) * 2015-07-06 2015-08-19 Ucb Biopharma Sprl Proteins
GB201513033D0 (en) * 2015-07-23 2015-09-09 Ucb Biopharma Sprl Proteins
KR20250053203A (ko) 2015-07-24 2025-04-21 글리크닉 인코포레이티드 향상된 상보체 결합을 갖는 규칙적으로 다형체화된 면역글로불린 fc 조성물을 생성하기 위한 인간 단백질 단편의 융합 단백질
AU2017213117A1 (en) * 2016-01-27 2018-07-19 CSL Behring Lengnau AG Recombinant IgG Fc multimers
EP3423572B1 (en) 2016-03-02 2023-11-29 Momenta Pharmaceuticals, Inc. Methods related to engineered fc constructs
DK3484514T3 (da) 2016-05-23 2024-01-29 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
AU2017279538A1 (en) 2016-06-07 2019-01-03 Gliknik Inc. Cysteine-optimized stradomers
AU2017300794A1 (en) 2016-07-22 2019-01-24 Gliknik Inc. Fusion proteins of human protein fragments to create orderly multimerized immunoglobulin fc compositions with enhanced fc receptor binding
CN110022898B (zh) 2016-12-09 2023-07-04 格利克尼克股份有限公司 用多价Fc化合物治疗炎性疾病的方法
JP7146771B2 (ja) 2017-01-06 2022-10-04 モメンタ ファーマシューティカルズ インコーポレイテッド 操作されたFcコンストラクトに関する組成物及び方法
CN113603780B (zh) * 2017-03-28 2022-07-01 礼进生物医药科技(上海)有限公司 用于增强肿瘤微环境中免疫应答的治疗剂和方法
US20210095006A1 (en) 2017-12-14 2021-04-01 CSL Behring Lengnau AG RECOMBINANT IgG Fc MULTIMERS FOR THE TREATMENT OF NEUROMYELITIS OPTICA
WO2020102251A1 (en) 2018-11-14 2020-05-22 Jn Biosciences Llc Multimeric hybrid fc proteins for replacement of ivig
GB201903767D0 (en) * 2019-03-19 2019-05-01 Quadrucept Bio Ltd Multimers, tetramers & octamers
AU2020344164A1 (en) 2019-09-13 2022-04-14 CSL Behring Lengnau AG Recombinant IgG Fc multimers for the treatment of immune complex-mediated kidney disorders
BR112022010096A2 (pt) * 2019-12-06 2022-09-06 CSL Behring Lengnau AG Composições estáveis de multímeros fc
CN115724985A (zh) * 2021-08-27 2023-03-03 三生国健药业(上海)股份有限公司 一种cdc平台抗体
CN120060370A (zh) * 2023-11-29 2025-05-30 上海科锐克医药科技有限公司 用于递送人vegf受体融合蛋白的基因递送载体及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160070165A (ko) * 2008-02-08 2016-06-17 메디뮨 엘엘씨 Fc 리간드 친화성이 감소된 항-IFNAR1 항체
EP2260057B1 (en) * 2008-03-13 2016-11-23 Biotest AG Anti-CD4 antibody dosage regimen for treating autoimmune disease
JP2012515556A (ja) * 2009-01-23 2012-07-12 バイオジェン・アイデック・エムエイ・インコーポレイテッド 低下したエフェクタ機能を有する安定化Fcポリペプチドおよび使用方法
EP2760891B1 (en) * 2011-09-26 2018-11-07 JN Biosciences LLC Hybrid constant regions
JP2015524821A (ja) * 2012-08-02 2015-08-27 ジェイエヌ バイオサイエンシーズ エルエルシー システイン変異及びμ尾部を介して多量体化した抗体又は融合タンパク質

Similar Documents

Publication Publication Date Title
JP2017509335A5 (enExample)
JP2017512063A5 (enExample)
RU2010122053A (ru) Иммуносупрессорные полипептиды и нуклеиновые кислоты
JP2016526909A5 (enExample)
RU2016139006A (ru) Мультимерные fc-белки
JP2019522465A5 (enExample)
HRP20220080T1 (hr) Poboljšane imunoglobulinske varijabilne domene koje vežu serumski albumin
JP2019516665A5 (enExample)
JP2021020905A5 (enExample)
RU2016139022A (ru) МУЛЬТИМЕРНЫЕ Fc-БЕЛКИ
RU2015129640A (ru) Связанные дисульфидом мультивалентные многофункциональные белки, содержащие молекулы гкгс класса 1
JP2020500015A5 (enExample)
JP2014506790A5 (enExample)
JP2005120106A5 (enExample)
FI3998285T3 (fi) Cd38:aan ja pd-l1:een sitoutuvia molekyylejä
RU2013140685A (ru) ВАРИАНТЫ Fc, СПОСОБЫ ИХ ПОЛУЧЕНИЯ
JP2020529841A5 (enExample)
JP2019512222A5 (enExample)
IL276286B1 (en) FC variants with improved binding to FCRN and extended half-life
IL309260B1 (en) Fusion proteins of human protein fragments to create orderly multimerized immunoglobulin fc compositions with enhanced complement binding
NZ606427A (en) Extended recombinant polypeptides and compositions comprising same
FI2968461T3 (fi) Fuusioproteiineja, jotka käsittävät pdgf:ää ja vegf:ää sitovia osia, ja menetelmiä niiden käyttämiseksi
JP2018514209A5 (enExample)
MX2009012319A (es) Polipeptidos que se unen a receptores fc con funciones efectoras modificadas.
JP2015146822A5 (enExample)